Price Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Price Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,143	Closed	-$739K	–	134
2018 Q2	$739K	Buy	+2,143	New	+$670K	0.36%	43
2015 Q2	–	Sell	-574	Closed	-$259K	–	168
2015 Q1	$259K	Buy	+574	New	+$243K	0.16%	135

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Price Capital Management's REGN Position: Q3 2018 in Review

Price Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2018, closing a stake of 2,143 shares — an estimated $739K sold.

Price Capital Management first reported a position in REGN in Q1 2015 and held it in 2 quarters. The position peaked at $739K in Q2 2018. 644 funds tracked by Wall St. Rank hold REGN as of Q3 2018.

Price Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Price Capital Management sold 2,143 Regeneron Pharmaceuticals shares in Q3 2018, an estimated $739K.
Price Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2015 and held it in 2 quarters.
Price Capital Management's Regeneron Pharmaceuticals position peaked at $739K in Q2 2018.
644 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2018.

Based on Price Capital Management's 13F filing for Q3 2018, filed 29 Oct 2018.